TapewireFind a company

person · Reporting owner

Svoronos Dawn

Disclosed activity across 7 companies

Tapewire entity
2603
SEC CIK
0001574579

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
PTC THERAPEUTICS, INC.PTCT · Entity 3803DirectorJune 09, 2022June 10, 2022
Xenon Pharmaceuticals Inc.XENE · Entity 2602DirectorSeptember 01, 2026September 04, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

PTC THERAPEUTICS, INC.

Report date June 09, 2022 · Filed June 10, 2022

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect29,017 Reported balance After 2022-06-09 transaction · row 1
1 source row

Row 1 · 2022-06-09 · Sale · Disposed 738 · Balance 29,017

F1: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 1,333 RSUs from a January 7, 2022 grant of 3,200 RSUs.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 1,333 RSUs from a January 7, 2022 grant of 3,200 RSUs.

Xenon Pharmaceuticals Inc.

Report date September 01, 2026 · Filed September 04, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common SharesSEC Table I · non-derivativeDirect31,373 Reported balance After 2026-09-01 transaction · row 1
1 source row

Row 1 · 2026-09-01 · Exercise / conversion · Acquired 5,144 · Balance 31,373

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.15 · Expires 2026-09-26Direct0 Reported balance After 2026-09-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-09-01 · Exercise / conversion · Disposed 5,144 · Balance 0

F1: The shares subject to the option are fully vested and exercisable.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option are fully vested and exercisable.

Past disclosures · reporting ended (5)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ACELYRIN, Inc.

Report date May 21, 2025 · Filed May 23, 2025

Section 16 reporting ended · disclosed 2025-05-23. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2025-05-21 transaction · row 1
1 source row

Row 1 · 2025-05-21 · Disposition to issuer · Disposed 15,000 · Balance 0

F1: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares.

Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.46 · Expires 2034-06-06Direct0 Reported balance After 2025-05-21 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2025-05-21 · Disposition to issuer · Disposed 92,158 · Balance 0

F3: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent.

F2: All of the shares subject to the option vest on the earlier of (i) June 7, 2025, or (ii) the day immediately preceding the next annual meeting of stockholders following the grant date of the option, subject to the Reporting Person's continued service as a director through the vesting date.

Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2033-05-03Direct0 Reported balance After 2025-05-21 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2025-05-21 · Disposition to issuer · Disposed 23,243 · Balance 0

F3: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent.

F4: 1/36 of the shares subject to the option vested on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.

Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.88 · Expires 2032-11-30Direct0 Reported balance After 2025-05-21 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2025-05-21 · Disposition to issuer · Disposed 155,450 · Balance 0

F3: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent.

F5: 1/48 of the shares subject to the option vested on January 1, 2023 and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service.

Filing footnotes · ownership attribution and instrument terms

F1: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares.

F2: All of the shares subject to the option vest on the earlier of (i) June 7, 2025, or (ii) the day immediately preceding the next annual meeting of stockholders following the grant date of the option, subject to the Reporting Person's continued service as a director through the vesting date.

F3: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent.

F4: 1/36 of the shares subject to the option vested on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.

F5: 1/48 of the shares subject to the option vested on January 1, 2023 and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service.

Adverum Biotechnologies, Inc.

Report date December 09, 2025 · Filed December 10, 2025

Section 16 reporting ended · disclosed 2025-12-10. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2025-12-09 transaction · row 1
1 source row

Row 1 · 2025-12-09 · Other · Disposed 5,000 · Balance 0

F1: In connection with the terms of an Agreement and Plan of Merger, dated as of October 24, 2025 (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's direct wholly owned subsidiary, Flying Tigers Acquisition Corporation ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $3.56 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR"), which represents the contractual right to receive up to two contingent cash payments of up to an aggregate of $8.91 per CVR, net to the stockholder in cash,

F2: (continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of both specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement") with Computershare Inc. and its affiliate, Computershare Trust Company, N.A, as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of December 9, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time").

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $128.20Direct0 Reported balance After 2025-12-09 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2025-12-09 · Disposition to issuer · Disposed 4,500 · Balance 0

F3: Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.00Direct0 Reported balance After 2025-12-09 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2025-12-09 · Disposition to issuer · Disposed 4,000 · Balance 0

F3: Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.90Direct0 Reported balance After 2025-12-09 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2025-12-09 · Disposition to issuer · Disposed 4,000 · Balance 0

F3: Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.60Direct0 Reported balance After 2025-12-09 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2025-12-09 · Disposition to issuer · Disposed 4,000 · Balance 0

F3: Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.32Direct0 Reported balance After 2025-12-09 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2025-12-09 · Disposition to issuer · Disposed 10,520 · Balance 0

F3: Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.32Direct0 Reported balance After 2025-12-09 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2025-12-09 · Disposition to issuer · Disposed 10,450 · Balance 0

F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option granted under a Company Equity Plan having an exercise price less than the Cash Consideration (each such option, a "Cash-Out Stock Option") that was outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, and in exchange for such cancellation, the holder of such Cash-Out Stock Option received (i) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting).

Filing footnotes · ownership attribution and instrument terms

F1: In connection with the terms of an Agreement and Plan of Merger, dated as of October 24, 2025 (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's direct wholly owned subsidiary, Flying Tigers Acquisition Corporation ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $3.56 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR"), which represents the contractual right to receive up to two contingent cash payments of up to an aggregate of $8.91 per CVR, net to the stockholder in cash,

F2: (continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of both specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement") with Computershare Inc. and its affiliate, Computershare Trust Company, N.A, as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of December 9, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time").

F3: Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time.

F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option granted under a Company Equity Plan having an exercise price less than the Cash Consideration (each such option, a "Cash-Out Stock Option") that was outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, and in exchange for such cancellation, the holder of such Cash-Out Stock Option received (i) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting).

ENDOCYTE INC

Report date December 21, 2018 · Filed December 21, 2018

Section 16 reporting ended · disclosed 2018-12-21. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2018-12-21 transaction · row 1 Sequence does not reconcile; account continuity is unresolved.
1 source row

Row 1 · 2018-12-21 · Disposition to issuer · Disposed 3,750 · Balance 0

F1: This restricted stock unit ("RSU") award provided for vesting and settlement 1/3 on the business day before each of the Company's three annual stockholder meetings following May 3, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Agreement and Plan of Merger, dated as of October 17, 2018 (the "Merger Agreement"), by and among Endocyte, Inc. (the "Company"), Novartis AG ("Novartis") and Edinburgh Merger Corporation, a wholly owned subsidiary of Novartis ("Merger Sub"), at the effective time (the "Effective Time") of the merger of Merger Sub with and into the Company, which Effective Time occurred on December 21, 2018, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.

Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2018-12-21 transaction · row 2 Sequence does not reconcile; account continuity is unresolved.
1 source row

Row 2 · 2018-12-21 · Disposition to issuer · Disposed 3,300 · Balance 0

F2: This RSU award provided for vesting and settlement 100% on the business day prior to the Company's annual stockholder meeting following May 3, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.81 · Expires 2028-05-03Direct0 Reported balance After 2018-12-21 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2018-12-21 · Disposition to issuer · Disposed 22,500 · Balance 0

F3: This Company stock option was scheduled to vest 1/3 on the business day before each of the Company's three annual stockholder meetings following May 3, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.81 · Expires 2028-05-03Direct0 Reported balance After 2018-12-21 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2018-12-21 · Disposition to issuer · Disposed 19,500 · Balance 0

F4: This Company stock option was scheduled to vest 100% on the business day prior to the Company's annual stockholder meeting following May 3, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: This restricted stock unit ("RSU") award provided for vesting and settlement 1/3 on the business day before each of the Company's three annual stockholder meetings following May 3, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Agreement and Plan of Merger, dated as of October 17, 2018 (the "Merger Agreement"), by and among Endocyte, Inc. (the "Company"), Novartis AG ("Novartis") and Edinburgh Merger Corporation, a wholly owned subsidiary of Novartis ("Merger Sub"), at the effective time (the "Effective Time") of the merger of Merger Sub with and into the Company, which Effective Time occurred on December 21, 2018, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.

F2: This RSU award provided for vesting and settlement 100% on the business day prior to the Company's annual stockholder meeting following May 3, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.

F3: This Company stock option was scheduled to vest 1/3 on the business day before each of the Company's three annual stockholder meetings following May 3, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

F4: This Company stock option was scheduled to vest 100% on the business day prior to the Company's annual stockholder meeting following May 3, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

Global Blood Therapeutics, Inc.

Report date October 05, 2022 · Filed October 06, 2022

Section 16 reporting ended · disclosed 2022-10-06. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2022-10-05 transaction · row 1
1 source row

Row 1 · 2022-10-05 · Disposition to issuer · Disposed 5,376 · Balance 0

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement.

F2: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect0 Reported balance After 2022-10-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2022-10-05 · Disposition to issuer · Disposed 3,600 · Balance 0

F3: Each restricted stock unit of the Issuer ("RSU") represented a contingent right to receive one share of Common Stock.

F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.68Direct0 Reported balance After 2022-10-05 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2022-10-05 · Disposition to issuer · Disposed 30,000 · Balance 0

F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.30Direct0 Reported balance After 2022-10-05 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2022-10-05 · Disposition to issuer · Disposed 7,500 · Balance 0

F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.75Direct0 Reported balance After 2022-10-05 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2022-10-05 · Disposition to issuer · Disposed 5,247 · Balance 0

F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.09Direct0 Reported balance After 2022-10-05 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2022-10-05 · Disposition to issuer · Disposed 5,600 · Balance 0

F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.30Direct0 Reported balance After 2022-10-05 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2022-10-05 · Disposition to issuer · Disposed 5,600 · Balance 0

F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement.

F2: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.

F3: Each restricted stock unit of the Issuer ("RSU") represented a contingent right to receive one share of Common Stock.

F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.

F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

MEDIVATION, INC.

Report date September 28, 2016 · Filed September 30, 2016

Section 16 reporting ended · disclosed 2016-09-30. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2016-09-28 transaction · row 1
1 source row

Row 1 · 2016-09-28 · Other · Disposed 21,206 · Balance 0

F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal.

F2: Includes 2,972 unvested shares subject to a restricted stock award.

Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.36 · Expires 2023-04-30Direct0 Reported balance After 2016-09-28 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2016-09-28 · Disposition to issuer · Disposed 30,000 · Balance 0

F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.

Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.60 · Expires 2023-06-28Direct0 Reported balance After 2016-09-28 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2016-09-28 · Disposition to issuer · Disposed 12,232 · Balance 0

F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.

Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.89 · Expires 2024-06-27Direct0 Reported balance After 2016-09-28 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2016-09-28 · Disposition to issuer · Disposed 9,584 · Balance 0

F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.

Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.82 · Expires 2024-10-15Direct0 Reported balance After 2016-09-28 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2016-09-28 · Disposition to issuer · Disposed 11,046 · Balance 0

F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.

Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.45 · Expires 2025-06-16Direct0 Reported balance After 2016-09-28 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2016-09-28 · Disposition to issuer · Disposed 6,284 · Balance 0

F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.

Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $58.89 · Expires 2026-06-22Direct0 Reported balance After 2016-09-28 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2016-09-28 · Disposition to issuer · Disposed 6,228 · Balance 0

F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal.

F2: Includes 2,972 unvested shares subject to a restricted stock award.

F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
September 01, 2026 Filed Sep 4, 2026 00:26 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionStock Option (Right to Buy) · Derivative 5,144 $0.00 Strike: $8.15 $0.00
Disclosure

SEC source: 0001193125-26-382412 · ownership.xml · derivative · entry 2

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 5,144 shares

Expires 2026-09-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable.

Read SEC document
September 01, 2026 Filed Sep 4, 2026 00:26 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionCommon Shares 5,144 $8.15 $41,923.60
Disclosure

SEC source: 0001193125-26-382412 · ownership.xml · nonDerivative · entry 1

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,373

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 03, 2026 Filed Jun 4, 2026 01:03 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 GrantRestricted Share Units · Derivative 1,593 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001193125-26-256118 · ownership.xml · derivative · entry 5

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,593

Underlying: Common Shares · 1,593 shares

Expires not disclosed

F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders.

F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders.

Read SEC document
June 03, 2026 Filed Jun 4, 2026 01:03 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 GrantShare Option (Right to Buy) · Derivative 10,507 $0.00 Strike: $53.46 $0.00
Disclosure

SEC source: 0001193125-26-256118 · ownership.xml · derivative · entry 4

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,507

Underlying: Common Shares · 10,507 shares

Expires 2036-06-02

F4 · derivative.exercise_date: Vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders.

Read SEC document
June 01, 2026 Filed Jun 4, 2026 01:03 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionRestricted Share Units · Derivative 2,645 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-256118 · ownership.xml · derivative · entry 3

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 2,645 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders.

F1 · derivative.exercise_date: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders.

F1 · derivative.expiration_date: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders.

Read SEC document
June 01, 2026 Filed Jun 4, 2026 01:03 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Tax withholdingCommon Shares 1,416 $53.41 $75,628.56
Disclosure

SEC source: 0001193125-26-256118 · ownership.xml · nonDerivative · entry 2

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,229

F2 · shares: Represents the number of Common Shares withheld by the issuer to satisfy income tax withholding and remittance obligations in connection with the net settlement of the RSUs, and does not represent a sale.

F3 · price: Represents the closing price of Common Shares on June 1, 2026 for purposes of net settlement calculations.

Read SEC document
June 01, 2026 Filed Jun 4, 2026 01:03 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionCommon Shares 2,645 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-256118 · ownership.xml · nonDerivative · entry 1

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,645

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders.

F1 · price: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders.

Read SEC document
December 09, 2025 Filed Dec 10, 2025 13:31 UTC Adverum Biotechnologies, Inc. ADVM · Entity 71889 Disposition to issuerStock Option (Right to Buy) · Derivative 10,450 Not disclosed Strike: $2.32 Not disclosed
Disclosure

SEC source: 0001574579-25-000004 · form4-12102025_061241.xml · derivative · entry 7

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,450 shares

Expires not disclosed

F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option granted under a Company Equity Plan having an exercise price less than the Cash Consideration (each such option, a "Cash-Out Stock Option") that was outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, and in exchange for such cancellation, the holder of such Cash-Out Stock Option received (i) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting).

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option granted under a Company Equity Plan having an exercise price less than the Cash Consideration (each such option, a "Cash-Out Stock Option") that was outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, and in exchange for such cancellation, the holder of such Cash-Out Stock Option received (i) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting).

F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option granted under a Company Equity Plan having an exercise price less than the Cash Consideration (each such option, a "Cash-Out Stock Option") that was outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, and in exchange for such cancellation, the holder of such Cash-Out Stock Option received (i) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting).

Read SEC document
December 09, 2025 Filed Dec 10, 2025 13:31 UTC Adverum Biotechnologies, Inc. ADVM · Entity 71889 Disposition to issuerStock Option (Right to Buy) · Derivative 10,520 Not disclosed Strike: $7.32 Not disclosed
Disclosure

SEC source: 0001574579-25-000004 · form4-12102025_061241.xml · derivative · entry 6

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,520 shares

Expires not disclosed

F3 · price: Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time.

F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time.

F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time.

Read SEC document
December 09, 2025 Filed Dec 10, 2025 13:31 UTC Adverum Biotechnologies, Inc. ADVM · Entity 71889 Disposition to issuerStock Option (Right to Buy) · Derivative 4,000 Not disclosed Strike: $15.60 Not disclosed
Disclosure

SEC source: 0001574579-25-000004 · form4-12102025_061241.xml · derivative · entry 5

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,000 shares

Expires not disclosed

F3 · price: Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time.

F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time.

F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time.

Read SEC document
December 09, 2025 Filed Dec 10, 2025 13:31 UTC Adverum Biotechnologies, Inc. ADVM · Entity 71889 Disposition to issuerStock Option (Right to Buy) · Derivative 4,000 Not disclosed Strike: $9.90 Not disclosed
Disclosure

SEC source: 0001574579-25-000004 · form4-12102025_061241.xml · derivative · entry 4

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,000 shares

Expires not disclosed

F3 · price: Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time.

F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time.

F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time.

Read SEC document
December 09, 2025 Filed Dec 10, 2025 13:31 UTC Adverum Biotechnologies, Inc. ADVM · Entity 71889 Disposition to issuerStock Option (Right to Buy) · Derivative 4,000 Not disclosed Strike: $37.00 Not disclosed
Disclosure

SEC source: 0001574579-25-000004 · form4-12102025_061241.xml · derivative · entry 3

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,000 shares

Expires not disclosed

F3 · price: Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time.

F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time.

F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time.

Read SEC document
December 09, 2025 Filed Dec 10, 2025 13:31 UTC Adverum Biotechnologies, Inc. ADVM · Entity 71889 Disposition to issuerStock Option (Right to Buy) · Derivative 4,500 Not disclosed Strike: $128.20 Not disclosed
Disclosure

SEC source: 0001574579-25-000004 · form4-12102025_061241.xml · derivative · entry 2

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,500 shares

Expires not disclosed

F3 · price: Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time.

F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time.

F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time.

Read SEC document
December 09, 2025 Filed Dec 10, 2025 13:31 UTC Adverum Biotechnologies, Inc. ADVM · Entity 71889 OtherCommon Stock 5,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001574579-25-000004 · form4-12102025_061241.xml · nonDerivative · entry 1

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: In connection with the terms of an Agreement and Plan of Merger, dated as of October 24, 2025 (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's direct wholly owned subsidiary, Flying Tigers Acquisition Corporation ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $3.56 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR"), which represents the contractual right to receive up to two contingent cash payments of up to an aggregate of $8.91 per CVR, net to the stockholder in cash,

F2 · kind: (continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of both specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement") with Computershare Inc. and its affiliate, Computershare Trust Company, N.A, as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of December 9, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time").

F1 · price: In connection with the terms of an Agreement and Plan of Merger, dated as of October 24, 2025 (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's direct wholly owned subsidiary, Flying Tigers Acquisition Corporation ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $3.56 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR"), which represents the contractual right to receive up to two contingent cash payments of up to an aggregate of $8.91 per CVR, net to the stockholder in cash,

F2 · price: (continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of both specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement") with Computershare Inc. and its affiliate, Computershare Trust Company, N.A, as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of December 9, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time").

Read SEC document
June 17, 2025 Filed Jun 20, 2025 16:24 UTC Adverum Biotechnologies, Inc. ADVM · Entity 71889 GrantStock Option (Right to Buy) · Derivative 10,450 $0.00 Strike: $2.32 $0.00
Disclosure

SEC source: 0001415889-25-017850 · form4-06202025_080619.xml · derivative · entry 1

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,450

Underlying: Common Stock · 10,450 shares

Expires 2035-06-16

F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable on the earlier of June 17, 2026 or the 2026 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date.

Read SEC document
June 05, 2025 Filed Jun 6, 2025 21:57 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 GrantRestricted Share Units · Derivative 2,645 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000950170-25-083317 · ownership.xml · derivative · entry 2

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,645

Underlying: Common Shares · 2,645 shares

Expires not disclosed

F2 · derivative.exercise_date: Each restricted share unit represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 4, 2026 or (ii) the day before the date of the issuer's 2026 annual meeting of shareholders.

F2 · derivative.expiration_date: Each restricted share unit represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 4, 2026 or (ii) the day before the date of the issuer's 2026 annual meeting of shareholders.

Read SEC document
June 05, 2025 Filed Jun 6, 2025 21:57 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 GrantShare Option (Right to Buy) · Derivative 17,012 $0.00 Strike: $30.73 $0.00
Disclosure

SEC source: 0000950170-25-083317 · ownership.xml · derivative · entry 1

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,012

Underlying: Common Shares · 17,012 shares

Expires 2035-06-04

F1 · derivative.exercise_date: Vesting 100% on the earlier of (i) June 4, 2026 or (ii) the day before the date of the issuer's 2026 annual meeting of shareholders.

Read SEC document
May 21, 2025 Filed May 23, 2025 20:06 UTC ACELYRIN, Inc. SLRN · Entity 79310 Disposition to issuerDirector Stock Option (right to buy) · Derivative 155,450 Not disclosed Strike: $5.88 Not disclosed
Disclosure

SEC source: 0001962918-25-000054 · wk-form4_1748030755.xml · derivative · entry 4

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 155,450 shares

Expires 2032-11-30

F3 · price: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent.

F5 · derivative.exercise_date: 1/48 of the shares subject to the option vested on January 1, 2023 and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service.

Read SEC document
May 21, 2025 Filed May 23, 2025 20:06 UTC ACELYRIN, Inc. SLRN · Entity 79310 Disposition to issuerDirector Stock Option (right to buy) · Derivative 23,243 Not disclosed Strike: $18.00 Not disclosed
Disclosure

SEC source: 0001962918-25-000054 · wk-form4_1748030755.xml · derivative · entry 3

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 23,243 shares

Expires 2033-05-03

F3 · price: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent.

F4 · derivative.exercise_date: 1/36 of the shares subject to the option vested on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.

Read SEC document
May 21, 2025 Filed May 23, 2025 20:06 UTC ACELYRIN, Inc. SLRN · Entity 79310 Disposition to issuerDirector Stock Option (right to buy) · Derivative 92,158 Not disclosed Strike: $4.46 Not disclosed
Disclosure

SEC source: 0001962918-25-000054 · wk-form4_1748030755.xml · derivative · entry 2

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 92,158 shares

Expires 2034-06-06

F3 · price: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent.

F2 · derivative.exercise_date: All of the shares subject to the option vest on the earlier of (i) June 7, 2025, or (ii) the day immediately preceding the next annual meeting of stockholders following the grant date of the option, subject to the Reporting Person's continued service as a director through the vesting date.

Read SEC document
May 21, 2025 Filed May 23, 2025 20:06 UTC ACELYRIN, Inc. SLRN · Entity 79310 Disposition to issuerCommon Stock 15,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001962918-25-000054 · wk-form4_1748030755.xml · nonDerivative · entry 1

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · price: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares.

Read SEC document
June 17, 2024 Filed Jun 20, 2024 16:47 UTC Adverum Biotechnologies, Inc. ADVM · Entity 71889 GrantStock Option (Right to Buy) · Derivative 10,520 $0.00 Strike: $7.32 $0.00
Disclosure

SEC source: 0001415889-24-017677 · form4-06202024_080622.xml · derivative · entry 1

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,520

Underlying: Common Stock · 10,520 shares

Expires 2034-06-16

F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable on the earlier of June 17, 2025 or the 2025 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date.

Read SEC document
June 07, 2024 Filed Jun 11, 2024 23:07 UTC ACELYRIN, Inc. SLRN · Entity 79310 GrantDirector Stock Option (right to buy) · Derivative 92,158 $0.00 Strike: $4.46 $0.00
Disclosure

SEC source: 0001962918-24-000087 · wk-form4_1718147244.xml · derivative · entry 1

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,158

Underlying: Common Stock · 92,158 shares

Expires 2034-06-06

F1 · derivative.exercise_date: All of the shares subject to the option vest on the earlier of (i) June 7, 2025, or (ii) the day immediately preceding the next annual meeting of stockholders following the grant date of the option, subject to the Reporting Person's continued service as a director through the vesting date.

Read SEC document
June 05, 2024 Filed Jun 5, 2024 21:41 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 GrantStock Option (Right to Buy) · Derivative 15,542 $0.00 Strike: $38.16 $0.00
Disclosure

SEC source: 0000950170-24-069462 · ownership.xml · derivative · entry 1

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,542

Underlying: Common Shares · 15,542 shares

Expires 2034-06-04

F1 · derivative.exercise_date: Vesting 100% on the earlier of (i) June 4, 2025 or (ii) the day before the date of the issuer's 2025 annual meeting of shareholders.

Read SEC document
August 24, 2023 Filed Aug 24, 2023 20:33 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 25,000 $38.70 $967,500.00
Disclosure

SEC source: 0000950170-23-044403 · ownership.xml · nonDerivative · entry 1

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

F1 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.70 to $38.79, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Read SEC document
June 09, 2023 Filed Jun 13, 2023 17:10 UTC Adverum Biotechnologies, Inc. ADVM · Entity 71889 GrantStock Option (Right to Buy) · Derivative 40,000 $0.00 Strike: $1.56 $0.00
Disclosure

SEC source: 0001209191-23-036813 · doc4.xml · derivative · entry 1

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2033-06-08

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 9, 2024 or the 2024 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date.

Read SEC document
June 02, 2023 Filed Jun 2, 2023 21:24 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 GrantStock Option (Right to Buy) · Derivative 18,475 $0.00 Strike: $38.96 $0.00
Disclosure

SEC source: 0000950170-23-026178 · ownership.xml · derivative · entry 1

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,475

Underlying: Common Shares · 18,475 shares

Expires 2033-06-01

F1 · derivative.exercise_date: Vesting 100% on the earlier of (i) June 1, 2024 or (ii) the day immediately preceding the day of the following year's annual meeting.

Read SEC document
May 09, 2023 Filed May 12, 2023 01:11 UTC ACELYRIN, Inc. SLRN · Entity 79310 OtherDirector Stock Option (right to buy) · Derivative 23,243 $0.00 Strike: $18.00 $0.00
Disclosure

SEC source: 0001209191-23-028882 · doc4.xml · derivative · entry 5

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,243

Underlying: Common Stock · 23,243 shares

Expires 2033-05-03

F2 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO.

F4 · derivative.exercise_date: 1/36 of the shares subject to the option vest on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.

F2 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO.

Read SEC document
May 09, 2023 Filed May 12, 2023 01:11 UTC ACELYRIN, Inc. SLRN · Entity 79310 OtherDirector Stock Option (right to buy) · Derivative 23,243 $0.00 Strike: $18.00 $0.00
Disclosure

SEC source: 0001209191-23-028882 · doc4.xml · derivative · entry 4

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 23,243 shares

Expires 2033-05-03

F2 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO.

F4 · derivative.exercise_date: 1/36 of the shares subject to the option vest on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.

F2 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO.

Read SEC document
May 09, 2023 Filed May 12, 2023 01:11 UTC ACELYRIN, Inc. SLRN · Entity 79310 OtherDirector Stock Option (right to buy) · Derivative 155,450 $0.00 Strike: $5.88 $0.00
Disclosure

SEC source: 0001209191-23-028882 · doc4.xml · derivative · entry 3

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 155,450

Underlying: Common Stock · 155,450 shares

Expires 2032-11-30

F2 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO.

F3 · derivative.exercise_date: 1/48 of the shares subject to the option vested on January 1, 2023 and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service.

F2 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO.

Read SEC document
May 09, 2023 Filed May 12, 2023 01:11 UTC ACELYRIN, Inc. SLRN · Entity 79310 OtherDirector Stock Option (right to buy) · Derivative 155,450 $0.00 Strike: $5.88 $0.00
Disclosure

SEC source: 0001209191-23-028882 · doc4.xml · derivative · entry 2

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 155,450 shares

Expires 2032-11-30

F2 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO.

F3 · derivative.exercise_date: 1/48 of the shares subject to the option vested on January 1, 2023 and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service.

F2 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO.

Read SEC document
May 09, 2023 Filed May 12, 2023 01:11 UTC ACELYRIN, Inc. SLRN · Entity 79310 PurchaseCommon Stock 15,000 $18.00 $270,000.00
Disclosure

SEC source: 0001209191-23-028882 · doc4.xml · nonDerivative · entry 1

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

F1 · shares: Reflects shares purchased through a directed share program in the Issuer's initial public offering of Common Stock (the "IPO").

Read SEC document
May 04, 2023 Filed May 5, 2023 00:24 UTC ACELYRIN, Inc. SLRN · Entity 79310 GrantDirector Stock Option (right to buy) · Derivative 23,243 $0.00 Strike: $18.00 $0.00
Disclosure

SEC source: 0001209191-23-027539 · doc4.xml · derivative · entry 1

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,243

Underlying: Class A Common · 23,243 shares

Expires 2033-05-03

F1 · derivative.exercise_date: 1/36 of the shares subject to the option vest on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.

F2 · derivative.underlying: Each share of Class A Common Stock shall be reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock.

Read SEC document
October 05, 2022 Filed Oct 6, 2022 20:20 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Disposition to issuerStock Option (Right to Buy) · Derivative 5,600 Not disclosed Strike: $22.30 Not disclosed
Disclosure

SEC source: 0000899243-22-033157 · doc4.xml · derivative · entry 7

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,600 shares

Expires not disclosed

F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

Read SEC document
October 05, 2022 Filed Oct 6, 2022 20:20 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Disposition to issuerStock Option (Right to Buy) · Derivative 5,600 Not disclosed Strike: $37.09 Not disclosed
Disclosure

SEC source: 0000899243-22-033157 · doc4.xml · derivative · entry 6

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,600 shares

Expires not disclosed

F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

Read SEC document
October 05, 2022 Filed Oct 6, 2022 20:20 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Disposition to issuerStock Option (Right to Buy) · Derivative 5,247 Not disclosed Strike: $64.75 Not disclosed
Disclosure

SEC source: 0000899243-22-033157 · doc4.xml · derivative · entry 5

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,247 shares

Expires not disclosed

F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

Read SEC document
October 05, 2022 Filed Oct 6, 2022 20:20 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Disposition to issuerStock Option (Right to Buy) · Derivative 7,500 Not disclosed Strike: $56.30 Not disclosed
Disclosure

SEC source: 0000899243-22-033157 · doc4.xml · derivative · entry 4

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,500 shares

Expires not disclosed

F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

Read SEC document
October 05, 2022 Filed Oct 6, 2022 20:20 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Disposition to issuerStock Option (Right to Buy) · Derivative 30,000 Not disclosed Strike: $38.68 Not disclosed
Disclosure

SEC source: 0000899243-22-033157 · doc4.xml · derivative · entry 3

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,000 shares

Expires not disclosed

F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

Read SEC document
October 05, 2022 Filed Oct 6, 2022 20:20 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Disposition to issuerRestricted Stock Units · Derivative 3,600 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-22-033157 · doc4.xml · derivative · entry 2

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,600 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit of the Issuer ("RSU") represented a contingent right to receive one share of Common Stock.

F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.

F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.

Read SEC document
October 05, 2022 Filed Oct 6, 2022 20:20 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Disposition to issuerCommon Stock 5,376 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-22-033157 · doc4.xml · nonDerivative · entry 1

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement.

F2 · price: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.

Read SEC document
June 28, 2022 Filed Jun 29, 2022 21:44 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 GrantStock Option (Right to Buy) · Derivative 18,000 $0.00 Strike: $30.11 $0.00
Disclosure

SEC source: 0001209191-22-039836 · doc4.xml · derivative · entry 1

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Shares · 18,000 shares

Expires 2032-06-27

F1 · derivative.exercise_date: 100% of the common shares subject to the option will vest on the earlier of (i) the first anniversary of grant date and (ii) the day immediately preceding the day of the Issuer's next annual general meeting of shareholders.

Read SEC document
June 21, 2022 Filed Jun 22, 2022 22:00 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 SaleCommon Stock 1,908 $27.24 $51,982.70
Disclosure

SEC source: 0000899243-22-023597 · doc4.xml · nonDerivative · entry 1

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,376

F1 · kind: This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 25, 2022 to cover the Reporting Person's tax obligations in connection with the vesting of 3,600 shares of Common Stock underlying the Reporting Person's RSUs as previously reported on the Form 4 filed by the Reporting Person on June 16, 2022.

F2 · price: Represents the weighted average sale price of the shares sold ranging from $26.80 to $27.69 per share, inclusive. The Reporting Person will provide, upon request by the Issuer, a security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
June 14, 2022 Filed Jun 16, 2022 22:00 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 GrantRestricted Stock Units · Derivative 3,600 $0.00 $0.00
Disclosure

SEC source: 0000899243-22-022889 · doc4.xml · derivative · entry 4

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,600

Underlying: Common Stock · 3,600 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F4 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 14, 2023 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended).

F4 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 14, 2023 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended).

Read SEC document
June 14, 2022 Filed Jun 16, 2022 22:00 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 GrantStock Option (Right to Buy) · Derivative 5,600 $0.00 Strike: $22.30 $0.00
Disclosure

SEC source: 0000899243-22-022889 · doc4.xml · derivative · entry 3

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,600

Underlying: Common Stock · 5,600 shares

Expires 2032-06-13

F3 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in equal monthly installments over a period of 12 months following June 14, 2022 for 11 months and the remaining 1/12th on the earlier of (i) June 14, 2023 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended).

Read SEC document
June 14, 2022 Filed Jun 16, 2022 22:00 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Exercise / conversionRestricted Stock Units · Derivative 3,600 $0.00 $0.00
Disclosure

SEC source: 0000899243-22-022889 · doc4.xml · derivative · entry 2

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,600 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F2 · derivative.exercise_date: The RSUs vested in a single installment on June 14, 2022.

F2 · derivative.expiration_date: The RSUs vested in a single installment on June 14, 2022.

Read SEC document
June 14, 2022 Filed Jun 16, 2022 22:00 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Exercise / conversionCommon Stock 3,600 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-22-022889 · doc4.xml · nonDerivative · entry 1

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,284

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
June 10, 2022 Filed Jun 14, 2022 16:22 UTC Adverum Biotechnologies, Inc. ADVM · Entity 71889 GrantStock Option (Right to Buy) · Derivative 40,000 $0.00 Strike: $0.99 $0.00
Disclosure

SEC source: 0001209191-22-036690 · doc4.xml · derivative · entry 1

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2032-06-09

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 10, 2023 or the 2023 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date.

Read SEC document
June 09, 2022 Filed Jun 10, 2022 20:06 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 738 $27.20 $20,074.34
Disclosure

SEC source: 0001415889-22-006410 · form4-06102022_010651.xml · nonDerivative · entry 1

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,017

F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 1,333 RSUs from a January 7, 2022 grant of 3,200 RSUs.

Read SEC document
May 16, 2022 Filed May 18, 2022 16:43 UTC Adverum Biotechnologies, Inc. ADVM · Entity 71889 PurchaseCommon Stock 30,000 $0.85 $25,578.00
Disclosure

SEC source: 0001209191-22-030075 · doc4.xml · nonDerivative · entry 1

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

F1 · price: Price reported is a weighted-average purchase price. The shares were purchased at prices ranging from $0.8402 to $0.8538. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

Read SEC document
January 07, 2022 Filed Jan 11, 2022 21:14 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 GrantStock Option (Right To Buy) · Derivative 12,000 $0.00 Strike: $38.10 $0.00
Disclosure

SEC source: 0001179110-22-000392 · edgar.xml · derivative · entry 3

Svoronos Dawn · CIK 0001574579 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2032-01-06

F3 · derivative.exercise_date: This option was granted on January 7, 2022 and vests over one year in twelve equal monthly installments, commencing on February 7, 2022.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.